Viral Hepatitis

You have full text access to this OnlineOpen article

Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus†

  1. Juan Macías1,
  2. Juan Berenguer2,
  3. Miguel A. Japón3,
  4. José A. Girón4,
  5. Antonio Rivero5,
  6. Luis F. López-Cortés6,
  7. Ana Moreno7,
  8. Mercedes González-Serrano8,
  9. José A. Iribarren9,
  10. Enrique Ortega10,
  11. Pilar Miralles2,
  12. José A. Mira1,
  13. Juan A. Pineda1,‡,*

Article first published online: 19 JUN 2009

DOI: 10.1002/hep.23136

Issue

Hepatology

Hepatology

Volume 50, Issue 4, pages 1056–1063, October 2009

Additional Information

How to Cite

Macías, J., Berenguer, J., Japón, M. A., Girón, J. A., Rivero, A., López-Cortés, L. F., Moreno, A., González-Serrano, M., Iribarren, J. A., Ortega, E., Miralles, P., Mira, J. A. and Pineda, J. A. (2009), Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology, 50: 1056–1063. doi: 10.1002/hep.23136

Author Information

  1. 1

    Infectious Diseases Unit, Hospital Universitario de Valme, Seville, Spain

  2. 2

    Infectious Diseases Unit, Hospital Universitario Gregorio Marañón, Madrid, Spain

  3. 3

    Pathology Department, Hospital Universitario Virgen del Rocío, Seville, Spain

  4. 4

    Infectious Diseases Unit, Hospital Universitario Puerta del Mar, Cadiz, Spain

  5. 5

    Infectious Diseases Unit, Hospital Universitario Reina Sofía, Cordoba, Spain

  6. 6

    Infectious Diseases Department, Hospital Universitario Virgen del Rocío, Seville, Spain

  7. 7

    Infectious Diseases Unit, Hospital Universitario Ramón y Cajal, Madrid, Spain

  8. 8

    Infectious Diseases Unit, Hospital Universitario Virgen de la Victoria, Malaga, Spain

  9. 9

    Infectious Diseases Unit, Hospital Donostia, San Sebastian, Spain

  10. 10

    Infectious Diseases Unit, Hospital General Universitario de Valencia, Valencia, Spain

  1. ‡

    fax: +34-955015757

*Infectious Diseases Unit, Hospital Universitario de Valme, Avda. Bellavista s/n, 41014-Seville, Spain

  1. †

    Potential conflict of interest: Nothing to report

  2. ‡

    fax: +34-955015757

Publication History

  1. Issue published online: 28 SEP 2009
  2. Article first published online: 19 JUN 2009
  3. Accepted manuscript online: 19 JUN 2009 12:00AM EST
  4. Manuscript Accepted: 11 JUN 2009
  5. Manuscript Received: 20 JAN 2009

Funded by

  • Consejería de Salud, Junta de Andalucía (exp. 0022/2007)
  • Fundación para la Investigación y la Prevención del SIDA en España (FIPSE, exp. 36789/08)
  • Ministerio de Sanidad y Consumo
  • Instituto de Salud Carlos III
  • Red de SIDA from Spain. Grant Number: ISCIII-RETIC RD06/006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (167K)

References

  • 1
    Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562–569.
  • 2
    Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708–1713.
  • 3
    Bonacini M, Louie S, Bzowej N, AR Wohl. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18: 2039–2045.
  • 4
    Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 49–57.
  • 5
    Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruiz-Morales J, Rivero A, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. HEPATOLOGY 2007; 46: 622–630.
  • 6
    Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. HEPATOLOGY 2001; 34: 283–287.
  • 7
    Martín-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128–133.
  • 8
    Mehta SH, Thomas DL, Torberson M, Brinkley S, Mirel L, Chaisson RE, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. HEPATOLOGY 2005; 41: 123–131.
  • 9
    Bräu N, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47–55.
  • 10
    Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11: 839–846.
  • 11
    Berenguer J, Bellón JM, Miralles P, Alvarez E, Castillo I, Cosín J, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2008; 46: 137–143.
  • 12
    Schiavini M, Angeli E, Mainini A, Zerbi P, Duca PG, Gubertini G, et al. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. HIV Med 2006; 7: 331–337.
  • 13
    Bonnard P, Lescure FX, Amiel C, Guiard-Schmid JB, Callard P, Gharakhanian S, et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepatol 2007; 14: 806–811.
  • 14
    Sulkowski M, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, Montes de Oca R, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21: 2209–2216.
  • 15
    Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, et al. Pegylated interferon α2a plus ribavirin versus pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009; 63: 1256–1263.
  • 16
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372–374.
  • 17
    Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702–706.
  • 18
    Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97–104.
  • 19
    Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC, Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 451–455.
  • 20
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–1313.
  • 21
    Lissen E, Clumeck N, Sola R, Mendes-Correa M, Montaner J, Nelson M, et al. Histological response to pegIFN alpha-2a (40 KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20: 2175–2181.
  • 22
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
  • 23
    Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008; 134: 803–811.
  • 24
    Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers R, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8. http://www.comparative-hepatology.com/content/3/1/8.
  • 25
    Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed July 2009.
  • 26
    Berenguer J, Alvarez-Pellicer J, López-Aldeguer J, Von-Wichman M, Quereda C, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in HIV/HCV-co-infected patients. In: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. [Abstract 60].
  • 27
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007; 45: 579–587.
View Full Article (HTML) Get PDF (167K)